NovoCure Limited (NVCR)
NASDAQ: NVCR · IEX Real-Time Price · USD
18.40
-0.08 (-0.43%)
At close: Jul 19, 2024, 4:00 PM
18.09
-0.31 (-1.68%)
Pre-market: Jul 22, 2024, 7:00 AM EDT
NovoCure Revenue
NovoCure had revenue of $525.66M in the twelve months ending March 31, 2024, with 0.61% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $138.50M with 13.36% year-over-year growth. In the year 2023, NovoCure had annual revenue of $509.34M.
Revenue (ttm)
$525.66M
Revenue Growth
+0.61%
P/S Ratio
3.77
Revenue / Employee
$361,775
Employees
1,453
Market Cap
1.98B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 509.34M | -28.50M | -5.30% |
Dec 31, 2022 | 537.84M | 2.81M | 0.53% |
Dec 31, 2021 | 535.03M | 40.67M | 8.23% |
Dec 31, 2020 | 494.37M | 143.05M | 40.72% |
Dec 31, 2019 | 351.32M | 103.25M | 41.62% |
Dec 31, 2018 | 248.07M | 71.04M | 40.13% |
Dec 31, 2017 | 177.03M | 94.14M | 113.57% |
Dec 31, 2016 | 82.89M | 49.80M | 150.52% |
Dec 31, 2015 | 33.09M | 17.60M | 113.60% |
Dec 31, 2014 | 15.49M | 5.13M | 49.53% |
Dec 31, 2013 | 10.36M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BrightSpring Health Services | 9.37B |
Premier | 1.34B |
10x Genomics | 625.45M |
Catalyst Pharmaceuticals | 411.35M |
Protagonist Therapeutics | 314.95M |
Arvinas | 71.30M |
Recursion Pharmaceuticals | 46.24M |
NVCR News
- 21 days ago - Novocure to Report Second Quarter 2024 Financial Results - Business Wire
- 7 weeks ago - METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival - Business Wire
- 2 months ago - TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany - Business Wire
- 2 months ago - Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon - Business Wire
- 2 months ago - Novocure Reports First Quarter 2024 Financial Results - Business Wire
- 3 months ago - Results of Novocure's METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024 - Business Wire
- 3 months ago - Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024 - Business Wire
- 4 months ago - Novocure to Report First Quarter 2024 Financial Results - Business Wire